On March 6, 2026, Hangzhou Xianweida Biotechnology Co., Ltd. (hereinafter referred to as "Xianweida Biotechnology"), a biopharmaceutical company specializing in the discovery and development of innovative therapies for metabolic diseases, announced today: the world's first cAMP biased GLP-1 receptor agonist enoglutide injection (Xianweida) ®) Approved for marketing by the National Medical Products Administration (NMPA), suitable for controlling diet and increasing physical activity
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablet
(3)Capsule
(4)Injection
(5)Liquid Drops
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code:BM-3-094
GLP-1 CAS 87805-34-3
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide GLP-1 Injections, please refer to the following website for detailed specifications and product information.
Product: https://www.bloomtechz.com/oem-odm/injection/glp-1-injections.html
On the basis of long-term weight management for adult overweight/obese patients.
Xianweiying @ is the world's first approved cAMP biased GLP-1 RA weight loss drug, with a biased mechanism that helps achieve efficient weight loss. The average weight loss of the Chinese population in 48 weeks reached 15.4% (after placebo correction, 15.1%), and 92.8% of patients achieved clinically significant weight loss. This marks a breakthrough in the field of healthy weight loss in China and provides a precise new path for scientific, long-term, and healthy weight loss.
Based on the world's first CAMP biased GLP-1 receptor activation mechanism, Xianweiying @ can selectively activate the cAMP signaling pathway and minimize B-arrestin recruitment, which is significantly different from traditional non biased GLP-1 RA. This mechanism directly brings two core advantages: first, the weight loss effect is strong and long-lasting, with no obvious plateau period throughout the process; second, while reducing weight, it synchronously improves metabolism and reduces the risk of chronic diseases, accurately meeting the core needs of healthy weight loss.
Kangzhe Pharmaceutical's self-developed INHBE small nucleic acid drug CMS-D008 has been approved by NMPA
Recently, Kangzhe Pharmaceutical Holdings Limited ("Kangzhe Pharmaceutical" or "the Group") announced that the innovative drug INHBE small nucleic acid drug CMS-D008 injection ("CMS-D008") independently developed by the Group has obtained a drug clinical trial approval notice issued by the National Medical Products Administration ("NMPA") of China.
NMPA agrees to conduct clinical trials of CMS-D008 injection for overweight or obesity. CMS-D008 is a subcutaneous injection siRNA drug that targets the inhibition of the expression of the inhibin subunit β E (INHBE) gene in the liver, downregulates the level of the INHBE encoded protein Activin E (ActinE), thereby reducing the activation of the fat metabolism pathway Activin E-ALK7 and effectively reducing lipid accumulation. Preclinical studies suggest that CMS-D008 efficiently and continuously inhibits INHBE expression. In obese animal models, significant weight loss and fat reduction effects are achieved without affecting muscles, and the safety is good; Showing good prospects for long-term high-quality weight loss without losing muscle mass. In the future, treatments for overweight/obesity, abdominal obesity, and related metabolic diseases can be developed.
CMS-D008 will collaborate with the self-developed innovative drug CMS-D005, which is currently in clinical development. CMS-D008 precisely inhibits INHBE gene expression, resulting in weight loss without muscle loss; As a dual agonist of GLP-1R/GCGR, CMS-DO05 can effectively reduce liver fat while reducing weight. The two work together to achieve efficient weight loss benefits and long-term results maintenance, jointly enhancing the research and development strength and product competitiveness of our group in the field of obesity/metabolic therapy. Relying on our mature network resources in the field of cardiovascular metabolic diseases, we accelerate the development and commercialization process of drugs and provide patients with more comprehensive and innovative treatment plans.